Oral vinorelbine (NVBo) plus cisplatin (CDDP) versus pemetrexed (PEM) plus CDDP followed by maintenance with single agent NVBo or PEM as first-line treatment of patients (pts) with advanced non-squamous non small cell lung cancer (NS-NSCLC): A cost minimization analysis from the Italian National Health System (NHS) perspective

被引：0

作者：

Favaretto, A. ^{[1
]}

Ciuffreda, L. ^{[2
]}

Nicolini, M. ^{[3
]}

Camerini, A. ^{[4
]}

Melotti, B. ^{[5
]}

Berardi, R. ^{[6
]}

Mencoboni, M. ^{[7
]}

Lucioni, C. ^{[8
]}

Mazzi, S. ^{[8
]}

Bennouna, J. ^{[9
]}

机构：

[1] Ist Oncol Veneto, Padua, Italy

[2] AO Citta Salute & Sci, Coes, Turin, Italy

[3] AUSL Rimini Osped Cervesi, Cattolica, Italy

[4] Azienda USL 12 Viareggio Osped Versilia, Viareggio, Italy

[5] AOU Policlin S Orsola Malpighi, Bologna, Italy

[6] AOU Osped Riuniti, Ancona, Italy

[7] AO Villa Scassi, Genoa, Italy

[8] Springer Healthcare Italia, Farmacoecon, Milan, Italy

[9] Inst Cancerol Ouest Site Rene Gauducheau, Nantes, France

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1506

引用

页码：S329 / S329

页数：1